Roche reports positive trial data for lung cancer drug Tecentriq

Roche has announced new phase III clinical trial data demonstrating the encouraging performance of its lung cancer therapy Tecentriq.

Results from the OAK study showed the drug was associated with a statistically significant and clinically meaningful improvement in overall survival compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed to respond effectively to platinum-based chemotherapy.

This means Tecentriq was able to meet its co-primary endpoints in the trial, while adverse events were shown to be consistent with those previously observed for this therapy.

Full results from this trial will be presented at an upcoming medical meeting in 2016 and will also be used to support future regulatory applications for the drug.

Dr Sandra Horning, chief medical officer and head of global product development at Roche, said: "These results add to the growing body of evidence that supports the role of Tecentriq as a potential new treatment for specific types of advanced NSCLC."

Roche currently has eight phase III studies underway evaluating Tecentriq's performance among patients with early and advanced stages of lung cancer, either alone or in combination with other treatments.

With? ?over? ?20? ?years? ?of? ?experience? ?within? ?the? ?pharmaceutical? ?market,? ?we? ?at? ?Zenopa? ?have? ?the knowledge,? ?skills? ?and? ?expertise? ?to? ?help? ?find? ?the? ?right? ?job? ?for? ?you.? ?To? ?find? ?out? ?more? ?about? ?the current? ?pharmaceutical? ?roles? ?we? ?have? ?available,? ?you? ?can? ?search? ?for? ?the? ?latest? ?job? ?roles, register? ?your? ?details,? ?or? ?contact? ?the? ?team? ?today.